Details werden geladen...
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia | FDA
The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.
Ähnliche Seiten
Axsome: FDA Approves AUVELITY For Treatment Of Agitation Associated With Dementia Due To Alzheimer's | 01.05.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/axsome-fda-approves-auvelity-for-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-1036093442
FDA approves leucovorin to treat rare cerebral folate deficiency - UPI.com
https://www.upi.com/Top_News/US/2026/03/10/fda-approves-leucovorin-calcium-cerebran-folate-deficiency/5031773158783/
Axsome: FDA Approves AUVELITY For Treatment Of Agitation Associated With Dementia Due To Alzheimer's | 01.05.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/axsome-fda-approves-auvelity-for-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-1036093442
FDA Approves First Treatment For Patients With Cerebral Folate Transport Deficiency
https://www.finanznachrichten.de/nachrichten-2026-03/67914496-fda-approves-first-treatment-for-patients-with-cerebral-folate-transport-deficiency-020.htmIncyte : FDA Approves Jakafi XR In Myelofibrosis, Polycythemia Vera, And Graft-Versus-Host Disease | 02.05.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/incyte-fda-approves-jakafi-xr-in-myelofibrosis-polycythemia-vera-and-graft-versus-host-disease-1036097457